

**Contact: Donna Morrow (CureDM)**  
**610-645-6796**  
[donna@curedm.com](mailto:donna@curedm.com)

**FOR IMMEDIATE RELEASE:**

## **CureDM Founder Claresa S. Levetan, MD receives Clinical Endocrinology Award**

Wynnewood, PA, March 27, 2007 -- CureDM Founder and Chief Scientific Officer, Dr. Claresa S. Levetan, is to receive the 2007 American College of Endocrinology Award for Distinction in Clinical Endocrinology, which recognizes her dedication in teaching. Dr. Levetan will accept the award during the American Association of Clinical Endocrinologists' Annual Meeting on April 14th, 2007. Dr. Levetan remarked, "It is indeed an honor to be recognized by such an outstanding group. I am proud to be among the leaders in the field who have previously achieved this award."

This is not Dr. Levetan's first award; in 2001, she received Roche Diagnostics' Diabetes Leadership Award for innovative diabetes research. She has also been internationally recognized for her work in translating science and technology into improved healthcare options for patients. Dr. Levetan has demonstrated that providing diabetic patients with A1C status and goals, can significantly improve clinical outcomes.

Dr. Levetan, a graduate of Emory University School of Medicine, serves as a healthcare consultant to the White House, members of Congress, and the Congressional Diabetes Caucus. She was an investigator on both the NIH's Diabetes Prevention Program and the Women's Health Initiative. She served on the steering committees of Medicare and the National Committee for Quality Assurance's (NCQA's) Diabetes Quality Improvement Project (DQIP) and on the Board of Directors of the American Association of Clinical Endocrinologists.

Dr. Levetan was previously Professor of Medicine and Chief of Endocrinology, Diabetes, and Metabolism at the Medical College of Pennsylvania Hospital and Drexel University College of Medicine. She is currently Clinical Professor at the Lankenau Institute for Medical Research and practices at Lankenau Hospital/Jefferson Health System. As CSO for CureDM, Inc., she is driving the development of a new therapeutic candidate for the treatment of diabetes. Loraine Upham, CEO of CureDM, said, "We are delighted that Claresa has received such well-deserved recognition of her work and are thrilled to have her as such an active member of our team."

### **About CureDM**

CureDM, Inc., located in the Lankenau Institute for Medical Research at the Lankenau Hospital campus in Wynnewood, PA, is developing a novel human peptide that stimulates the production of new, insulin-producing islets within the pancreas. This could provide a significant therapeutic benefit for both type 1 and type 2 diabetic patients. For more information about CureDM, visit [www.curedm.com](http://www.curedm.com).